62 results about "Chondroitin sulfate A" patented technology

The invention discloses a production method of a fish cartilage extract for preventing and treating osteoarthritis. According to the method, enzymolysis is carried out on fish cartilages by using mixed enzymes; trapping with an ultrafiltration membrane to obtain an extract containing low-molecular-weight chondroitin sulfate of which the molecular weight is less than 1000 Dalton and collagen peptide. In the method, a compound enzyme hydrolysis technology is adopted, so that synchronous hydrolysis of the chondroitin sulfate and collagen is realized, and comprehensive utilization of the fish cartilages is realized. The obtained product is low-molecular-weight chondroitin sulfate, so that the problem of low bioavailability of the chondroitin sulfate on the aspect of clinical application is solved. The extract can remarkably improve the symptoms of osteoarthritis and has good health care and treatment effects.

The invention provides a placenta targeted delivery system. The placenta targeted delivery system comprises a hydrophobic core, a monolayer lipid molecular layer wrapping the hydrophobic core and a hydrophilic shell. The hydrophobic core comprises a hydrophobic polymer and a targeted delivery object loaded by the hydrophobic polymer, and the targeted delivery object includes at least one of a pregnancy drug and an ultrasound contrast agent. The hydrophilic shell is an amphiphilic macromolecular compound grafted with a polypeptide of targeted placenta-like chondroitin sulfate A, the hydrophobicend of the amphiphilic macromolecular compound is interspersed in the monolayer lipid molecular layer, and the hydrophilic end of the amphiphilic macromolecular compound is linked to the polypeptidethrough an amido bond. The polypeptide is exposed outside the monolayer lipid molecular layer, wherein the amino acid sequence of the polypeptide is selected from one or more of amino acid sequences shown in SEQ ID NO: 1-SEQ ID NO: 3. The invention further provides a preparation method of the placenta targeted delivery system and application of the placenta targeted delivery system to diagnosis and treatment of a pregnancy disorder caused by the placenta.

The invention provides a preparation, separation and purification method of sea cucumber fucosan sulfate and chondroitin sulfate oligosaccharide. The method comprises the following steps: taking sea cucumber sulfated polysaccharide extracted from sea cucumbers as a raw material, adjusting the pH value of sea cucumber sulfated polysaccharide solution to 5.0-6.0, heating and degrading the solution with 110-115 DEG C high pressure steam for 60-90 min to enable fucosan sulfate to be degraded into oligosaccharide and performing ultrafiltration separation to obtain fucosan sulfate oligosaccharide; adjusting the pH value of ultrafiltration trapped fluid with the molecular weight of more than 5 kDa to 3.0-4.0, performing thermal degradation with 120-130 DEG C high pressure steam for 90-120 min andperforming concentration and freeze drying, so as to obtain sea cucumber fucosyl chondroitin sulfate oligosaccharide. According to the method, the steps of ion chromatographic separation, gel chromatographic purification, desalination and the like of fucosan sulfate and chondroitin sulfate in the sea cucumbers are saved, and the degradation, separation and purification of sea cucumber fucosan sulfate and chondroitin sulfate can be further completed, so that the preparation process is greatly simplified.

The invention relates to the field of pharmacy, particularly a compound glucosamine sulfate dispersible tablet preparation, wherein the main compositions include glucosamine sulfate and chondroitin sulfate, the auxiliary materials include excipient (e.g. starch and microcrystalline cellulose), disintegrating agent (e.g. cross-linked polyplasdone), lubricant (e.g. magnesium stearate) and humectant (e.g. anhydrous alcohol).

The invention relates to a technology for preparing high-purity chondroitin sulfate from animal organ, and particularly relates to a method for preparing high-purity chondroitin sulfate A from rabbit ear cartilage. The method comprises the following steps: skinning and fleshing the rabbit ear to obtain fresh rabbit ear cartilage; performing degreasing, trypsin enzymolysis, ethanol precipitation and anion exchange resin purification to obtain high-purity chondroitin sulfate A with molecular weight of 16-59kDa. The method provided by the invention is used for preparing chondroitin sulfate A from rabbit ear cartilage, has the characteristics of abundant sources of raw material, high product yield and high purity, and can meet the need for high-purity chondroitin sulfate A in the medical market.

The invention relates to an ophthalmic gel containing chondroitin sulfate and a method for preparing the same. The ophthalmic gel comprises chondroitin sulfate and taurine in effective dose and an aqueous gel substrate in proper amount. Compared with eyedrop, the ophthalmic gel has the advantages of good biocompatibility, small stimulation, simple preparation process and the like.

The invention discloses a chondroitin sulfate A nano-selenium micelle particle, and a preparation method and application thereof, which belong to the technical field of medical nanometer materials. The preparation method comprises the steps of adopting chondroitin sulfate A as a carrier, combining nano-selenium on the chondroitin sulfate A through physical adsorption so as to form the nano-selenium micelle particle, wherein the mass fraction of selenium is 0.1 percent to 25 percent. The chondroitin sulfate A nano-selenium micelle provided by the invention combines dual pharmacological activity of the chondroitin sulfate A and the nano-selenium, so that the toxicity of inorganic selenium is reduced, and the bioavailability is improved; meanwhile, by combining the biological activity of the chondroitin sulfate A, the chondroitin sulfate A nano-selenium micelle particle can be better developed to be a novel nanomicelle preparation for preventing and improving osteoarthrosis.

The invention discloses a fucosylated chondroitin sulfate oligosaccharide glycocluster with a structure show in general formula Q in the description. Definitions of substituent groups are detailed inthe description. The glycocluster compound is synthesized from chondroitin sulfate A salt as a raw material by acidolysis, protecting group operation and glycosylation in sequence on the basis of molecules of multifunctional groups as molecular skeletons. The glycocluster can simulate activity of natural glycosaminoglycan based on glycocluster effect, and can be applied to the medical field due tostructural certainty.

The present invention relates to pharmaceutical formulations containing a combination of specific high-molecular weight hyaluronic acid derivatives and chondroitin sulfate to be used in the treatment of osteoarthritis, of subchondral damage, osteoporosis, synovitis, tenosynovitis, tendinitis, tendinosis, as an intra-articular washing liquid and as a viscous substitute of synovial fluid following osteochondral surgery. These formulations are also suitable for the treatment of interstitial cystitis.

The invention provides peptide-drug conjugate of target placenta-like chondroitin sulfate A. The peptide-drug conjugate comprises a small molecule drug part, a peptide part and a connecting sub-part connected with the small molecule drug part and the peptide part, wherein peptide corresponding to the peptide part can target the placenta-like chondroitin sulfate A specifically, and the amino acid sequence of the peptide is selected from one or more of amino acid sequences shown as SEQ ID NO:1 to SEQ ID NO:3. The peptide-drug conjugate can target inappropriately-expressed target tissue of the placenta-like chondroitin sulfate A specifically, a drug is controlled to be released near the target tissue, and the toxic and side effects of the drug on normal tissue are reduced. The invention further provides a preparation method and application of the peptide-drug conjugate.

The invention discloses recombinant strains expressing a chondroitin 4-sulfotransferase gene and an applicationof the recombinant strain, and relates to the technical field of bioengineering. Chondroitin 4-sulfotransferase gene with the amino acid sequence shown in SEQ ID NO.1 is expressed with Escherichia coli or bacillus subtilis as a host, four recombinant strains are constituted, the high-efficiency expression of chondroitin 4-sulforansferase gene is realized, and final enzyme activity respectively reaches 41.3 U/mL, 32.8 U/mL, 36.5 U/mL and 50.2 U/mL. By using the enzyme as a catalyst, chondroitin sulfate A is catalyzed and synthesis in one step with chondroitin as a substrate, the final conversion efficiency reaches 80%. The method has potential and quite wide values in industrial synthesis of chondroitin sulfate A.

The invention discloses a preparation technology of a chondroitin sulfate A nano selenium freeze-dried powder injection, and belongs to the technical field of preparation of biomedical preparations. According to the adopted scheme, chondroitin sulfate A serves as a carrier to carry nano selenium particles obtained by reduction of sodium selenite and L-ascorbic acid for reaction in water so as to generate chondroitin sulfate A nano selenium liquid; unreacted substances in the prepared chondroitin sulfate A nano selenium liquid are removed through a molecular sieve, then filtering is conducted to remove bacteria and impurities, after physical characteristics are checked, the chondroitin sulfate A nano selenium liquid is split-charged into penicillin bottles, half plug-compressing is conducted, then vacuum freeze-drying treatment is conducted, plug-compressing is conducted for compressing aluminum caps, and the chondroitin sulfate A nano selenium freeze-dried powder injection is prepared,and stored in a frozen mode for standby application. According to the preparation technology, the process is simple, the quality is stable and controllable, physicochemical properties of prepared products are stable, and the preparation technology is suitable for industrial scale production.

A technology for shortening the extracting time of chondroitin sulfate comprises the following steps: (1) cartilage pretreatment; (2) dual enzymolysis: regulating pH (Potential of Hydrogen) value to be 8.8 to 9.3, adding alkaline protease 2709, stirring at a stirring speed of 20 to 60 rpm, and carrying out enzymolysis; regulating the pH value to be 8.4 to 8.8, adding activated porcine pancreas, stirring at the stirring speed of 20 to 60 rpm, and carrying out enzymolysis; (3) deproteinization: heating to 70 to 80 DEG C, stirring at the stirring speed of 90 to 110 rpm, regulating pH to an isoelectric point, treating for 10 to 30 minutes, stopping stirring, and standing; (4) filter pressing; (5) disk type centrifuging; (6) ion exchange; (7) eluting; (8) refining of the chondroitin sulfate. According to the technology disclosed by the invention, on the technological basis that the chondroitin sulfate is extracted through a dual enzymolysis method in the prior art and by improving a technological path and technological parameters and adopting a proper stirring speed, the enzymolysis speed is increased, and the enzymolysis time is shortened, so that the extracting time is shortened, andthe yield is increased.

A highly purified and specific glycosaminoglycan degrading enzyme, chondroitinase AC, and to a lesser extent, chondroitinase B, can be used in the treatment of metastatic cancers and in other disorders characterized by angiogenesis. The enzymatic removal of chondroitin sulfates A and C, and to a lesser extent, chondroitin sulfate B, from cell surfaces directly decreases the ability of tumor cells to invade blood vessels and thus prevents the formation of metastatic, or secondary tumors; inhibits tumor cell growth; and decreases angiogenesis by inhibiting both endothelial cell proliferation and capillary formation. Decreasing the formation of new blood vessels into the tumor in turn decreases the potential for tumor growth, and further decreases the ability of tumor cells to invade the bloodstream. These effects are opposite to the prometastatic effects of tumor-secreted heparanase.

The invention discloses a chondroitinase ABC producing recombinant yeast strain and application thereof and belongs to the technical field of bioengineering. According to the chondroitinase ABC producing recombinant yeast strain, chondroitinase ABC from Proteus vulgaris ATCC33420 is subjected to heterogeneous expression, and with pPIC9K carriers and through induction of methanol, secretory expression of the chondroitinase ABC in pichia pastoris GS115 can be achieve; by means of a designed chondroitinase ABC-enzymatic membrane reactor, efficient and continuous production of small-molecular chondroitin sulfate can be achieved, the chondroitinase ABC can be recycled and reutilized, and the production cost can be greatly reduced. By taking food-grade yeast as host strains, the chondroitinase ABC producing recombinant yeast strain can be safe and reliable, provide effective references for industrialized and green production of small-molecular chondroitin sulfate A, B and C, and meanwhile, save energy, reduce emission and achieve significant economic and social benefits.

The invention provides a novel fucosylated chondroitin sulfate FCS hm and a preparation method and an application thereof. The fucosylated chondroitin sulfate has the molecular weight of 50-200 kDa and has the sulfate content of 20-40%; a main chain of the fucosylated chondroitin sulfate is mainly composed of chondroitin sulfate A and chondroitin sulfate E. The FCS hm is mainly composed of four structural fragments, and a side chain contains 1-5 fucoses. The FCS hm exhibits good anticoagulant and antithrombotic activities through an endogenous coagulation pathway, is similar to low-molecular-weight heparin, and has inhibitory effects on FIIa and FXa mediated by antithrombin III. In addition, the FCS hm has high affinity with fibroblast growth factors FGF1 and FGF2, and has anti-angiogenesis effect. The preparation process of the compound provided by the invention has the advantages of low cost, simple operation and easy industrialized production.

The invention discloses a preparation method of polysulfated chondroitin sulfate, which comprises the steps of preparation of polysulfated chondroitin sulfate, separation and purification, formamide removal, decolorization, precipitation, lyophilization and the like. According to the invention, a chlorosulfonic acid- formamide mixed solution is adopted to performing sulfonation and heat degradation on chondroitin sulfate, then alcohol precipitation, filtration, decolorization and the like are carried out, and further purificatoion is conducted to obtain polysulfated chondroitin sulfate which can improve bone and joint function. The sulfonation and the degradation reaction are separated, firstly chlorosulfonic acid and formamide are added for sulfonation, and then heating is carried out fordegradation, and then through multi-step alcohol precipitation and filtration, polysulfated chondroitin sulfate meeting key quality indexes such as the molecular weight, the sulfur-carboxyl ratio, glucuronic acid and free sulfate content is obtained, has a high sulfonated chondroitin content of more than 70%. The chondroitin sulfate has a high degree of sulfation and is stable in nature and is not easily degraded by natural chondrosulphatase. The weight average molecular weight Mw is 7300-9300 Da, and the prepared polysulfated chondroitin sulfate has a good joint function improvement effect and can be used to maintain the joint cartilage integrity of humans and animals.

The invention discloses a powder injection of medium and/or low molecular weight chondroitin sulfate, in which the average molecular weight of the adopted chondroitin sulfate is in a scope of 2,000-30,000 daltons. The powder injection may be medium and/or low molecular weight chondroitin sulfate A,C or pharmaceutic salt of them, and the powder injection may also contain the its pharmaceutically acceptable auxiliary material. Because the molecular weight of the medium and/or low molecular weight chondroitin sulfate in the inventive powder injection is obviously less than the national standard of the chondroitin sulfate, thus it overcomes shortcoming of big molecular weight fluctuation of the ordinary chondroitin sulfate; it has more notable pharmaceutical role, more helpful for the absorption of the human body; and the powder injection may greatly raise the shelf-life, accordingly thoroughly solving its hidden trouble of going bad or reducing the effect in the storing and transport process.

The invention provides a placenta-like chondroitin sulfate A targeted delivery system, and further provides a preparation method and application of the placenta-like chondroitin sulfate A targeted delivery system. The placenta-like chondroitin sulfate A targeted delivery system comprises a serum albumin layer and a saccharide molecule, the saccharide molecule adheres to the serum albumin layer, and the serum albumin layer is further grafted with polypeptides of targeted placenta-like chondroitin sulfate A, wherein the polypeptides are grafted with serum albumins in the serum albumin layer through biotin-avidin specific binding. The amino acid sequence of the polypeptides is selected from one or more of amino acid sequences shown in SEQ ID NO: 1-SEQ ID NO: 3. The targeted delivery system iscapable of specifically targeting tissue which is inappropriately expressed by the placenta-like chondroitin sulfate A.

The invention relates to a bio-capsule for treating secondary hyperlipemia and a preparation method. Raw materials of active ingredients of the bio-capsule include commom banana pericarp, oenanthe javanica, radix clerodendri philippini, lotus petiole, biondia henryi, henbit, radix dipsaci, common seseli herb, crepis rigescens, crataegus root, all grass of anderson cirrhopetalum, tilia, twig and leaf of java bishopwood, lettuce seeds, chondroitin sulfate a, pantethine and lifibrate. The bio-capsule for treating the secondary hyperlipemia has the advantages that traditional Chinese medicines with efficacy of clearing heat, detoxifying, dispersing blood stasis, dredging collateral, removing food retention, harmonizing stomach, invigorating spleen, promoting digestion, nourishing liver and kidney, strengthening muscles and bones, conditioning blood vessels and the like are combined reasonably and used to cooperate with western medicine ingredients, by the aid of combination of the medicines, metabolic waste in blood can be cleared, the blood can be purified, lipid metabolism of a human body can be improved, decomposition course of lipid can be accelerated, fat accumulation in the human body can be decreased, blood lipid level can be lowered, complications like cardiovascular and cerebrovascular diseases and the like can be prevented, and proved by clinical verification, the bio-capsule is free of toxic, side or untoward effect and is applicable to wide popularization and application.